News & Events
Review of the ReGen Menaflex
Preliminary findings and recommendations regarding FDA's review and clearance of ReGen Biologics Inc.'s submission to market a device for use in treating injuries to the meniscus (knee cartilage).
Transcript for FDA's Media Briefing on the FDA's Review of the ReGen Menaflex
Persons with disabilities having problems accessing the Attachment may contact Tina Gilliam, 301-796-5217 for assistance.